Stryker Corporation $SYK Position Lowered by Bank Julius Baer & Co. Ltd Zurich

Key Points

• Bank Julius Baer reduced its Stryker stake by 6.2% in the third quarter, selling 23,147 shares and retaining 348,155 shares worth approximately $96.1 million. Institutional investors collectively own 77.09% of the company.
• Stryker’s third-quarter revenue rose 7.6% year over year to $6.52 billion, but revenue and adjusted EPS of $3.52 missed consensus estimates. The company also lowered its 2026 organic sales-growth and adjusted-EPS forecasts amid weaker joint-replacement demand and operational disruptions.
• Shares opened at $291.56, while analysts maintained a “Moderate Buy” consensus with an average price target of $355.84. Stryker recently paid a quarterly dividend of $0.88 per share, representing a 1.2% annualized yield.

Bank Julius Baer & Co. Ltd Zurich cut its stake in Stryker Corporation (NYSE:SYK - Free Report) by 6.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 348,155 shares of the medical technology company's stock after selling 23,147 shares during the period. Bank Julius Baer & Co. Ltd Zurich owned 0.09% of Stryker worth $96,075,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Community Bank & Trust Waco Texas boosted its holdings in shares of Stryker by 2.3% in the second quarter. Community Bank & Trust Waco Texas now owns 1,395 shares of the medical technology company's stock worth $439,000 after acquiring an additional 31 shares during the period. Cornerstone Financial Management LLC increased its position in shares of Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company's stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. NWF Advisory Services Inc. raised its stake in Stryker by 2.3% in the second quarter. NWF Advisory Services Inc. now owns 1,472 shares of the medical technology company's stock worth $463,000 after buying an additional 33 shares in the last quarter. Harold Davidson & Associates Inc. boosted its holdings in shares of Stryker by 0.4% in the 1st quarter. Harold Davidson & Associates Inc. now owns 8,668 shares of the medical technology company's stock valued at $2,848,000 after acquiring an additional 34 shares during the last quarter. Finally, Private Harbour Investment Management & Counsel LLC raised its position in Stryker by 0.9% during the second quarter. Private Harbour Investment Management & Counsel LLC now owns 3,927 shares of the medical technology company's stock worth $1,236,000 after acquiring an additional 34 shares during the period. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Stock Down 0.1%

Shares of SYK stock opened at $291.56 on Monday. The stock has a market cap of $111.83 billion, a price-to-earnings ratio of 31.05, a PEG ratio of 1.89 and a beta of 0.78. The firm's 50-day moving average is $292.83 and its 200-day moving average is $324.51. Stryker Corporation has a 52-week low of $267.00 and a 52-week high of $389.33. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 2.18.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.55 by ($0.03). Stryker had a return on equity of 23.74% and a net margin of 13.78%. The company had revenue of $6.52 billion for the quarter, compared to the consensus estimate of $6.62 billion. During the same period in the prior year, the business earned $3.19 earnings per share. The firm's revenue for the quarter was up 7.6% on a year-over-year basis. Sell-side analysts predict that Stryker Corporation will post 14.85 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. Stryker's dividend payout ratio (DPR) is currently 37.49%.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

Analyst Upgrades and Downgrades

SYK has been the topic of a number of recent research reports. Citigroup reaffirmed a "market outperform" rating on shares of Stryker in a research report on Friday. UBS Group initiated coverage on Stryker in a report on Tuesday, July 28th. They issued a "buy" rating and a $400.00 price target for the company. Stifel Nicolaus decreased their price objective on shares of Stryker from $360.00 to $330.00 and set a "buy" rating on the stock in a research report on Wednesday, September 30th. BTIG Research reduced their price target on shares of Stryker from $316.00 to $304.00 and set a "buy" rating on the stock in a research report on Friday. Finally, Needham & Company LLC cut their price target on Stryker from $418.00 to $359.00 and set a "buy" rating on the stock in a research note on Friday. Sixteen investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $355.84.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 300,000 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the sale, the director owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider directly owned 6,102 shares of the company's stock, valued at $2,005,178.22. The trade was a 6.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 351,267 shares of company stock worth $118,197,701. Corporate insiders own 4.60% of the company's stock.

Stryker Company Profile

Stryker Corporation NYSE: SYK is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company's product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.